"Spiriva Respimat" in complex therapy of chronic obstructive pulmonary disease
The research objective is to estimate «Spiriva Respimat» efficiency in complex therapy of chronic obstructive pulmonary disease patients in comparison with «Spiriva Handi Haler». 55 patients at the age of 45 to 94 with a medium severe and severe chronic obstructive pulmonary disease stage in the stabilization period were included in the research. All patients had complex therapy according to the chronic obstructive pulmonary disease stage. The «Spiriva Respimat» was included in complex therapy in the dose of 5 µg once a day for 25 patients of the first group. 30 patients of the second group had 18 µg of «Spiriva Handi Haler». At the beginning of the research and in 28 days of therapy clinical picture, spirometry results, peak-fluorometry, oxygen saturation, dyspnea intensity according to Modified Medical Research Council, Chronic obstructive pulmonary disease Assessment Test, 6-minute walk test were estimated. Both groups show reliable and comparable increase of respiratory function indicators. forced expiratory volume in 1 s in the first group increased from 53,91±6,53% due size to 62,66±18,81% due size (р<0,05); in the second group forced expiratory volume in 1 s at the beginning of the research was 47,05±12,97% due size, in 28 days - 54,31±10,46% due size (р<0,05). 8 patients with a combination of chronic obstructive pulmonary disease and bronchial asthma with reversible obstruction were revealed in the first group whose increase of forced expiratory volume in 1 s against the background of therapy which included «Spiriva Respimat» was reliably higher than in the group as a whole (20,5±2,58% due size vs. 8,36±9,49% due size (р<0,05). The improvement of respiratory function indicators at patients of the first group was accompanied by decrease of dyspnea intensity (-0,7 point according to Modified Medical Research Council), decrease of chronic obstructive pulmonary disease Assessment Test values by 4,3±0,14 points, 6-minute walk test increase by 78,12 m. «Spiriva Respimat» in chronic obstructive pulmonary disease complex therapy contributes to reliable decrease of bronchial obstruction, decreases dyspnea intensity, negative disease influence on patient’s life quality, increases tolerance to physical activities. Positive dynamics of respiratory function indicators when taking 5 µg dose of «Spiriva Respimat» has no reliable difference from that against the background of «Spiriva Handi Haler» in the dose of 18 µg a day. The «Spiriva» application is the most efficient in the «Respimat» form at patients with chronic obstructive pulmonary disease and bronchial asthma combination according to the results of clinicofunctional study.